BioStock: Evaxion comments on new strategic focus

Now that Per Norlén has taken over as CEO of Evaxion Biotech, the Danish immuno-oncology company has announced a shift in strategic focus aimed at channeling the company’s resources into its lead clinical assets within personalised cancer immunotherapy. Meanwhile, the infectious disease programmes will be developed in partnerships rather than brought into clinical development by Evaxion. BioStock got in touch with the new CEO to learn more about their plans.

Read the interview with Per Norlén at biostock.se:

Evaxion comments on new strategic focus - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/